ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointest... ( EXTON Pa. July 8 /- ViroPharma In...)

HOME >> BIOLOGY >> TECHNOLOGY

ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs

Date:7/8/2008

EXTON, Pa., July 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) has been informed by U.S. Food and Drug Administration (FDA) that the July 23, 2008 meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology is not intended to discuss specifically ViroPharma's Vancocin(R) (vancomycin hydrochloride capsules) or any other drug products. Rather, FDA has informed ViroPharma that FDA's Office of Generic Drugs (OGD) will only present for the Committee's consideration issues of general applicability to all locally acting drugs that treat gastrointestinal (GI) conditions. FDA also informed ViroPharma that any resulting recommendations by the Committee will be similarly general in nature. Additionally, ViroPharma has been advised that it will be afforded no more time to speak at the meeting than is afforded to any other member of the public, consistent with the non-product specific focus of the meeting. ViroPharma understands that the time to be provided to any one speaker will be very limited.

Based on FDA's statements to ViroPharma regarding the purpose of this meeting, made by both Committee staff and FDA's Office of Chief Counsel, ViroPharma will not discuss Vancocin at this meeting. Given ViroPharma's experience in this area, and the limited time available to speakers at the meeting, ViroPharma today submitted a letter to the Committee to aid its consideration of the general issue of bioequivalence methods for locally acting GI drugs. Among other things, ViroPharma's letter notes important issues that must be addressed in this complex area of bioequivalence method development, and attaches for the Committee's review a letter sent to FDA last year by the Infectious Diseases Society of Ameri
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
2. ViroPharma to Present at Two Upcoming Healthcare Conferences
3. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
4. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
7. ViroPharma to Present at the BIO CEO & Investor Conference
8. ViroPharma Provides 2008 Outlook
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. Vasogen Provides Corporate Update
11. Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home

Post Your Comments:

ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointest...( EXTON Pa. July 8 /- ViroPharma In...)